THPO and myelofibrosis: In chronic myelo-proliferative neoplasms, sustained by enhanced THPO/c-Mpl signaling, a THPOR antagonist (LCP4) has been shown to deplete malignant myelofibrosis in hematopoietic stem and progenitor cells [40].